Phosphodiesterase (PDE) inhibitors market is anticipated to grow at a significant CAGR during the forecast period. The PDE is found in the cytosol, plasma membranes, endoplasmic reticulum, nuclear membranes, and cytoskeleton. Majorly, the two types of PDE inhibitors including the selective and non-selective are being discovered as possible treatments for various indications, such as chronic obstructive pulmonary disease (COPD), Alzheimer’s disease, and other ailments. Thus, such novel application of these inhibitors in the treatment of various diseases is promising a strong market growth during the forecast period. Another pivotal factor that is driving the global PDE inhibitors market growth includes the rise in the prevalence of erectile dysfunction disorder. According to the World Health Organization, about 150 million people have been affected by erectile dysfunction across the globe and the number is projected to reach 230 million by 2025. It is a common medical condition affecting about 15% of men each year.
To Request a Sample of our Report on Phosphodiesterase (PDE) Inhibitors Market: https://www.omrglobal.com/request-sample/phosphodiesterase-pde-inhibitors-market
Some key players operating in the market include Bayer AG, Eli Lilly and Co., GlaxoSmithKline Plc, and Pfizer Inc., among others. These players are eyeing to strengthen their position in the market by adopting various strategies as mergers and acquisitions, partnerships, collaborations, new product launch and development in the existing product portfolio, and so on. For instance, in July 2018, Adamis Pharmaceuticals Corp. (Adamis) announced that it has been conducting pre-IND development work for a fast-dissolving sublingual tablet containing tadalafil, which is a drug used to treat erectile dysfunction. Further, in September 2020, Aspargo Laboratories, Inc. acquired the international rights to Sildenafil oral spray for the treatment of erectile dysfunction.
Market Coverage
- The market number available for – 2021-2028
- Base year- 2021
- Forecast period- 2022-2028
- Segment Covered
- Regions Covered- Globally
Competitive Landscape: Bayer AG, Eli Lilly and Co., GlaxoSmithKline Plc, and Pfizer Inc., among others.
A full Report of Phosphodiesterase (PDE) Inhibitors Market is Available @ https://www.omrglobal.com/industry-reports/phosphodiesterase-pde-inhibitors-market
Phosphodiesterase (PDE) Inhibitors Market by Segmentation
By Type
- Selective PDE Inhibitors
- PDE-1
- PDE-2
- PDE-3
- PDE-4
- PDE-5
- Others
- Non-Selective PDE Inhibitors
By Route of Administration
- Oral
- Topical
- Others
By Application
- CVD
- Erectile Dysfunction
- Pulmonary Hypertension
- Respiratory Disease
- Benign Prostate Hyperplasia
- Others
Phosphodiesterase (PDE) Inhibitors Market by Region
Regional Analysis
North America
- United States
- Canada
Europe
- UK
- Germany
- Spain
- France
- Italy
- Rest of Europe
Asia-Pacific
- India
- China
- Japan
- South Korea
- Rest of APAC
Rest of the World
Reasons to buy from us –
- We cover more than 15 major industries, further segmented into more than 90 sectors.
- More than 120 countries are for analysis.
- Over 100+ paid data sources mined for investigation.
- Our expert research analysts answer all your questions before and after purchasing your report.
For More Customized Data, Request for Report Customization @ https://www.omrglobal.com/report-customization/phosphodiesterase-pde-inhibitors-market
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.
Media Contact:
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact no: +91 7803040404
